Kari Johansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kari Johansen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
A Nicoll
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
1 shared publication- Anand Krishnan
Centre for Community Medicine All India Institute of Medical Sciences New Delhi India
1 shared publication Anh Nhi Tran
A Department of Microbiology , Public Health Agency of Sweden , Solna , Sweden
1 shared publicationB C Ciancio
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
1 shared publicationBarbro Österlin
A Department of Microbiology , Public Health Agency of Sweden , Solna , Sweden
1 shared publication- David J. Spiro
Fogarty International Center, National Institutes of Health, Bethesda, MD, USA
1 shared publication
Latest Publications
- Open Access
- 20 December 2017
- Published by Taylor & Francis in Infectious Diseases
- Vol. 50 (5) , 361-371
Impact on affected families and society of severe rotavirus infections in Swedish children assessed in a prospective cohort study
Background: Few prospective cohort studies have estimated the overall impact of severe rotavirus gastroenteritis (RVGE) leading to hospitalization on families and society. We assessed human and economic resources needed to care for an affected average child aged <5 years in Sweden. Methods: The study was conducted in Astrid Lindgren Children’s Hospital which serves approximately 14% of all Swedish children <5 years of age. All children admitted with acute gastroenteritis in the study period were tested for rotavirus. Health care consumption was collected prospectively and publically available unit costs used to calculate direct costs. Non-medical and indirect costs were collected in interviews with families using a standardized questionnaire during the hospital stay and approximately 14 days post-discharge. Results: 144/206 children (70%) with laboratory-confirmed RVGE were included. The median age was 14 months. The average total cost per hospitalized child was €3894, of which €2169 (56%) was due to direct healthcare-related costs (including Emergency Department visits and in-patient care), €104 (2%) to non-medical direct costs and €1621 (42%) to indirect costs due to productivity loss. Carers of children with severe RVGE were absent from work on average five days per study child: four days during hospitalization of affected child and one day due to gastroenteritis in the carer. Conclusions: Costs for RVGE are dominated by direct costs which are similar to some other countries in Europe, but indirect costs due to productivity loss are also important, and should be considered in decisions to introduce rotavirus vaccines into national vaccination programmes.
- 20 December 2017
- Published by Taylor & Francis in Infectious Diseases
- Vol. 50 (5) , 361-371
Open AccessImpact on affected families and society of severe rotavirus infections in Swedish children assessed in a prospective cohort study
Background: Few prospective cohort studies have estimated the overall impact of severe rotavirus gastroenteritis (RVGE) leading to hospitalization on families and society. We assessed human and economic resources needed to care for an affected average child aged <5 years in Sweden. Methods: The study was conducted in Astrid Lindgren Children’s Hospital which serves approximately 14% of all Swedish children <5 years of age. All children admitted with acute gastroenteritis in the study period were tested for rotavirus. Health care consumption was collected prospectively and publically available unit costs used to calculate direct costs. Non-medical and indirect costs were collected in interviews with families using a standardized questionnaire during the hospital stay and approximately 14 days post-discharge. Results: 144/206 children (70%) with laboratory-confirmed RVGE were included. The median age was 14 months. The average total cost per hospitalized child was €3894, of which €2169 (56%) was due to direct healthcare-related costs (including Emergency Department visits and in-patient care), €104 (2%) to non-medical direct costs and €1621 (42%) to indirect costs due to productivity loss. Carers of children with severe RVGE were absent from work on average five days per study child: four days during hospitalization of affected child and one day due to gastroenteritis in the carer. Conclusions: Costs for RVGE are dominated by direct costs which are similar to some other countries in Europe, but indirect costs due to productivity loss are also important, and should be considered in decisions to introduce rotavirus vaccines into national vaccination programmes.
- Open Access
- 20 October 2017
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 27 (suppl_3)
Introduction of new vaccines: How can storytelling help?
The introduction of a new vaccine into immunisation programmes may benefit from combining facts from what is known about the disease and the newly developed vaccine with storytelling techniques describing why vaccination against the disease is needed. The presentation will describe why preparing carefully for the introduction of a new vaccine can be crucial for the success of the immunisation programme.
- 20 October 2017
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 27 (suppl_3)
Open AccessIntroduction of new vaccines: How can storytelling help?
The introduction of a new vaccine into immunisation programmes may benefit from combining facts from what is known about the disease and the newly developed vaccine with storytelling techniques describing why vaccination against the disease is needed. The presentation will describe why preparing carefully for the introduction of a new vaccine can be crucial for the success of the immunisation programme.
- Open Access
- 15 October 2009
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 14 (41) , 19361
Pandemic influenza A(H1N1) 2009 vaccines in the European Union
Pandemic vaccines from four manufacturers are now available for use within the European Union (EU). Use of these vaccines will protect individuals and reduce the impact on health services to more manageable levels. The majority of the severely ill will be from known risk groups and the best strategy will be to start vaccinating in line with the recommendation from the European Union Health Security Committee prioritising adults and children with chronic conditions, pregnant women and healthcare workers. The composition of authorised vaccines is reviewed in this article. The vaccine strain in all authorised pandemic vaccines worldwide is based on the same initial isolate of influenza A/California/7/2009 (H1N1)v but the vaccines differ in conditions for virus propagation, antigen preparation, antigen content and whether they are adjuvanted or not. The vaccines are likely to be effective since no significant genetic or antigenic drift has occurred and there are already mechanisms for estimating clinical effectiveness. Influenza vaccines have good safety records and no safety concerns have so far been encountered with any of the vaccines developed. However, special mechanisms have been devised for the early detection and rigorous investigation of possible significant side effects in Europe through post-marketing surveillance and analysis. Delivery of the vaccines to the risk groups will pose difficulties where those with chronic illnesses are not readily identifiable to the healthcare services. There is considerable scope for European added value through Member States with excess vaccines making them available to other states.
- 15 October 2009
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 14 (41) , 19361
Open AccessPandemic influenza A(H1N1) 2009 vaccines in the European Union
Pandemic vaccines from four manufacturers are now available for use within the European Union (EU). Use of these vaccines will protect individuals and reduce the impact on health services to more manageable levels. The majority of the severely ill will be from known risk groups and the best strategy will be to start vaccinating in line with the recommendation from the European Union Health Security Committee prioritising adults and children with chronic conditions, pregnant women and healthcare workers. The composition of authorised vaccines is reviewed in this article. The vaccine strain in all authorised pandemic vaccines worldwide is based on the same initial isolate of influenza A/California/7/2009 (H1N1)v but the vaccines differ in conditions for virus propagation, antigen preparation, antigen content and whether they are adjuvanted or not. The vaccines are likely to be effective since no significant genetic or antigenic drift has occurred and there are already mechanisms for estimating clinical effectiveness. Influenza vaccines have good safety records and no safety concerns have so far been encountered with any of the vaccines developed. However, special mechanisms have been devised for the early detection and rigorous investigation of possible significant side effects in Europe through post-marketing surveillance and analysis. Delivery of the vaccines to the risk groups will pose difficulties where those with chronic illnesses are not readily identifiable to the healthcare services. There is considerable scope for European added value through Member States with excess vaccines making them available to other states.